Cefmetazole Sodium for Injection

None

The main ingredient of this product is cefmetazole sodium, and its chemical name is: (6R,7R)-7-[2-[(cyanomethyl)thio]acetylamino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt

This product is white to light yellow powder or lump.

This product is suitable for the treatment of the following infections caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella morganii, Providencia, Peptostreptococcus, Bacteroides, Prevotella (except Prevotella biloba) that are sensitive to cefmetazole sodium: 1. Sepsis 2. Acute bronchitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory diseases 3. Cystitis, pyelonephritis 4. Peritonitis 5. Cholecystitis, cholangitis 6. Bartholinitis, intrauterine infection, adnexitis, parametritis 7. Cellulitis around the jaws, jaw inflammation In the clinical studies (including double-blind trials) of 2,819 cases of intravenous injection, intravenous drip and intramuscular injection in 137 hospitals in Japan, the clinical results of 1,409 cases that can be judged as effective and belong to the approved indications of this product are as follows (for refractory or severe infections, the daily dose is increased to 4 grams (potency) for adults and 150 mg (potency) for children according to symptoms)/kg body weight): 1. Sepsis: The total effective rate for sepsis caused by Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae is 80.6% (25/31), and the dosage is 2-4g per day for adults and 50-150mg/kg for children. 2. Respiratory system infection: The total effective rate for respiratory tract infection caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella morganii, Providencia, etc. is 79.7% (267/335). The dosage for drip or intravenous injection is 2-4g per day. In the double-blind trial, the efficacy of this product has been verified. 3. Biliary tract infection: This product is well excreted into bile and can reach a high concentration in bile. The total effective rate for cholecystitis and cholangitis caused by Escherichia coli and Klebsiella pneumoniae is 83.1% (49/59). The dosage is 2~4g per day. 4. Peritonitis: The total effective rate for peritonitis caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides, Prevotella (except Prevotella biloba), etc. is 87.596 (161/184). Most of them are intravenous drips, and the dosage is 2~4g per day. 5. Urinary tract infection: The total effective rate for cystitis and pyelonephritis caused by Escherichia coli, Klebsiella pneumoniae, Proteus, Morganella kurschniki, Providencia, etc. is 73.1% (302/413). The dosage is mostly 1~2g per day. The results of a double-blind controlled trial on chronic complicated urinary tract infections have proved the efficacy of this product. 6. Gynecology and Obstetrics: The total effective rate for vestibular glanditis, intrauterine infection, adnexitis, and parametrial tissue inflammation caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Peptostreptococcus, Bacteroides, and Prevotella (except Prevotella biloba) is 94.796 (232/245). The dosage is usually 2-4g per day. 7. Oral Surgery: The total effective rate for perimandibular cellulitis and jaw inflammation caused by Peptostreptococcus is 83.896 (119/142). The dosage is usually 2-4g per day.

Usually for adults, 1-2 grams (titer) per day, divided into 2 intravenous injections or intravenous drips. Usually for children, 25-100 mg (titer)/kg body weight per day, divided into 2-4 intravenous injections or intravenous drips. In addition, for refractory or severe infections, the daily dose can be increased to 4 grams (titer) for adults and 150 mg (titer)/kg body weight for children according to symptoms, and administered in 2-4 doses. For intravenous injection, 1 gram (titer) of this agent is dissolved in 10 ml of sterile water for injection, normal saline or glucose injection, and injected slowly. In addition, this agent can be added to the rehydration for intravenous drip. When dissolving the intravenous drip agent (100 ml bottle), do not use distilled water for injection (because the solution is not isotonic).

1. Shock (less than 0.01%): Shock may occur (initial symptoms: discomfort, abnormal sensation in the mouth, wheezing, dizziness, urge to defecate, tinnitus, sweating, etc.), so it is necessary to observe carefully. If abnormalities occur, the drug should be discontinued and treated appropriately. 2. Acute renal failure (unknown incidence): Occasionally, severe renal damage such as acute renal failure may occur, so regular examinations should be performed and observations should be observed. If BUN and blood creatinine increase, the drug should be discontinued and treated appropriately. .3. Agranulocytosis (unknown incidence) and hemolytic anemia (unknown incidence): Agranulocytosis and hemolytic anemia may occur, so regular examinations should be performed and observations should be observed. If abnormalities occur, the drug should be discontinued and treated appropriately. .4. Pseudomembranous colitis (less than 0.01%): Occasionally, severe colitis such as pseudomembranous colitis with bloody stools may occur (initial symptoms: abdominal pain, frequent diarrhea), so it is necessary to observe carefully. If abnormalities occur, the drug should be discontinued and treated appropriately. .5. Interstitial pneumonia (unknown incidence) and PIE syndrome (unknown incidence): Interstitial pneumonia and PIE syndrome with fever, cough, dyspnea, abnormal chest X-ray, eosinophilia, etc., if such symptoms occur, the drug should be discontinued immediately and appropriate treatment such as adrenocortical hormone preparations should be given. .6. Other side effects Mucocutaneous and ocular syndrome: Mucocutaneous and ocular syndrome (Stenens-Johnson syndrome) has been reported with other cephem antibiotics.

(This product is contraindicated in patients with a history of anaphylactic shock to its ingredients. In principle, this product should not be given to patients with a history of allergy to its ingredients or cephalosporin antibiotics. If it must be used, it should be used with caution.

Alcohol: Drinking alcohol may cause disulfiram-like effects (facial flushing, palpitations, dizziness, headache, nausea, etc.) [Avoid drinking alcohol during and for at least 1 week after administration.] Diuretics (furosemide, etc.): May enhance renal damage.

Keep in a dark, airtight container in a cool place. Validity period: 24 months

Calculated as C15H17N7O5S3 0.25g

Sichuan Hexin Pharmaceutical Co., Ltd.

• Founded in:

  2002-11-08

• Address:

  No. 12, Wuke East 3rd Road, Chengdu

• Tax NO.:

  91510100743617685C

• Registered Funds:

  19.3 million yuan

• Website:

  Log in to view

• Email:

  Log in to view